×
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
NASDAQ:IONS

Ionis Pharmaceuticals (IONS) Stock Forecast, Price & News

$37.63
+0.98 (+2.67%)
(As of 05/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$36.31
$37.65
50-Day Range
$31.71
$43.00
52-Week Range
$25.04
$44.42
Volume
1.62 million shs
Average Volume
1.16 million shs
Market Capitalization
$5.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.78
30 days | 90 days | 365 days | Advanced Chart
Receive IONS News and Ratings via Email

Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Ionis Pharmaceuticals logo

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; Flamingo Therapeutics, Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IONS
CUSIP
46433010
Employees
660
Year Founded
N/A

Sales & Book Value

Annual Sales
$810 million
Cash Flow
$0.09 per share
Book Value
$5.00 per share

Profitability

Net Income
$-28.60 million
Pretax Margin
-0.41%

Debt

Price-To-Earnings

Miscellaneous

Free Float
138,395,000
Market Cap
$5.34 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/04/2022
Today
5/27/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.86 out of 5 stars

Medical Sector

739th out of 1,424 stocks

Pharmaceutical Preparations Industry

353rd out of 681 stocks

Analyst Opinion: 2.1Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

Is Ionis Pharmaceuticals a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 3 sell ratings, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Ionis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View analyst ratings for Ionis Pharmaceuticals
or view top-rated stocks.

When is Ionis Pharmaceuticals' next earnings date?

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Ionis Pharmaceuticals
.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings data on Wednesday, May, 4th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.68) by $0.22. The firm had revenue of $142 million for the quarter, compared to analysts' expectations of $122.46 million. Ionis Pharmaceuticals had a negative trailing twelve-month return on equity of 0.46% and a negative net margin of 0.36%. The business's revenue was up 26.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.64) earnings per share.
View Ionis Pharmaceuticals' earnings history
.

What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?

Ionis Pharmaceuticals updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $612.37 million.

What price target have analysts set for IONS?

8 brokerages have issued 1-year price targets for Ionis Pharmaceuticals' shares. Their forecasts range from $26.00 to $65.00. On average, they expect Ionis Pharmaceuticals' share price to reach $41.88 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price.
View analysts' price targets for Ionis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Ionis Pharmaceuticals' key executives?
Ionis Pharmaceuticals' management team includes the following people:
  • Dr. Brett P. Monia Ph.D., Founder, CEO & Director (Age 61, Pay $1.34M)
  • Ms. Elizabeth L. Hougen, Exec. VP of Fin. & CFO (Age 60, Pay $862.13k)
  • Mr. Patrick R. O'Neil Esq., Exec. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 48, Pay $822.93k)
  • Dr. Stanley T. Crooke, Scientific Advisor (Age 77, Pay $1.31M)
  • Ms. B. Lynne Parshall Esq., J.D., Sr. Strategic Advisor & Director (Age 68, Pay $1.03M)
  • Dr. Richard S. Geary, Exec. VP & Chief Devel. Officer (Age 64, Pay $868.91k)
  • Ms. Onaiza Cadoret-Manier, Exec. VP and Chief Product Strategy & Operations Officer (Age 57)
  • Mr. Joel Edwards, VP of Corp. Operations (Age 61)
  • Mr. Darren Gonzales, Chief Accounting Officer & Sr. VP
  • Dr. C. Frank Bennett, Exec. VP & Chief Scientific Officer (Age 65)
What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.53%), Bellevue Group AG (6.99%), Clearbridge Investments LLC (4.57%), ARK Investment Management LLC (4.36%), Tweedy Browne Co LLC (2.06%) and First Trust Advisors LP (1.14%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends for Ionis Pharmaceuticals
.

Which institutional investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Privium Fund Management B.V., Candriam Luxembourg S.C.A., Bellevue Group AG, Eversept Partners LP, Woodline Partners LP, International Biotechnology Trust PLC, and Altrinsic Global Advisors LLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include Brett P Monia, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, and Spencer R Berthelsen.
View insider buying and selling activity for Ionis Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Ionis Pharmaceuticals stock?

IONS stock was acquired by a variety of institutional investors in the last quarter, including Tweedy Browne Co LLC, Clearbridge Investments LLC, Goldman Sachs Group Inc., Assenagon Asset Management S.A., Simplex Trading LLC, Vanguard Group Inc., Russell Investments Group Ltd., and TD Asset Management Inc..
View insider buying and selling activity for Ionis Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $37.63.

How much money does Ionis Pharmaceuticals make?

Ionis Pharmaceuticals has a market capitalization of $5.34 billion and generates $810 million in revenue each year. The company earns $-28.60 million in net income (profit) each year or ($0.200010) on an earnings per share basis.

How many employees does Ionis Pharmaceuticals have?

Ionis Pharmaceuticals employs 660 workers across the globe.

What is Ionis Pharmaceuticals' official website?

The official website for Ionis Pharmaceuticals is www.ionispharma.com.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at (760) 931-9200, via email at [email protected], or via fax at 760-603-2700.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.